RxDoctor Payments Data

Evan Butlin, MD

Pulmonary Disease · Wyomissing, PANPI 1396001087

Payments from drug & device makers

$5,390in general payments, 2019–2025

Across 101 payments — averaging $53.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$3K
  • AstraZeneca$477
  • GSK$337
  • Insmed, Inc.$227
  • Regeneron Healthcare Solutions, Inc.$205
  • Sanofi$202
  • plus $668 from 16 others

What the payments were for

  • Travel & lodging$75714%
  • Food & beverage$2,03338%
  • Education$2,60048%

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,390 in reported general payments places this provider in the 65th percentile of 703 pulmonary disease providers in Pennsylvania.

See all pulmonary disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$138,050
Medicare patients
536
Services billed
1,555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breztri AerosphereBudesonide/Glycopyr/Formoterol57$48,893
Trelegy ElliptaFluticasone/Umeclidin/Vilanter68$42,750
Stiolto RespimatTiotropium Br/Olodaterol Hcl29$24,171
Breo ElliptaFluticasone/Vilanterol49$22,052
DuleraMometasone/Formoterol25$10,066
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$9,734
SymbicortBudesonide/Formoterol Fumarate33$9,436
Advair HfaFluticasone Propion/Salmeterol24$7,099
Combivent RespimatIpratropium/Albuterol Sulfate12$6,255
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate34$6,205
Albuterol Sulfate HfaAlbuterol Sulfate207$4,669
Fluticasone-SalmeterolFluticasone Propion/Salmeterol32$3,211
Ventolin HfaAlbuterol Sulfate42$2,345
Doxycycline Monohydrate20$303
Prednisone55$156

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$337$74,536134 claims
AstraZenecaBreztri Aerosphere, Symbicort$477$58,32990 claims
MerckDulera$81$10,06625 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 703 pulmonary disease providers in Pennsylvania.

Other pulmonary disease in Wyomissing

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →